{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:19Z","timestamp":1790916979140,"version":"4.1.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100003239","name":"Robert J. and Claire Pasarow Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003239","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Disease Oriented Scholars Award"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1P30 CA142543-01"],"award-info":[{"award-number":["1P30 CA142543-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01232-1","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T08:03:58Z","timestamp":1786003438000},"page":"681-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK4\/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities"],"prefix":"10.1007","volume":"21","author":[{"given":"Luis","family":"Chinea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-3163","authenticated-orcid":false,"given":"Isaac S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"5","key":"1232_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI J Natl Cancer Inst. 2014;106(5):dju055. https:\/\/doi.org\/10.1093\/jnci\/dju055.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"1232_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1524-4741.2009.00822.x","volume":"15","author":"CA Parise","year":"2009","unstructured":"Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999\u20132004. Breast J. 2009;15(6):593\u2013602. https:\/\/doi.org\/10.1111\/j.1524-4741.2009.00822.x.","journal-title":"Breast J"},{"issue":"10","key":"1232_CR3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","volume":"20","author":"M Giuliano","year":"2019","unstructured":"Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30420-6.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1232_CR4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.5306\/wjco.v5.i5.990","volume":"5","author":"A Milani","year":"2014","unstructured":"Milani A. Overcoming endocrine resistance in metastatic breast cancer: current evidence and future directions. World J Clin Oncol. 2014;5(5):990\u20131001. https:\/\/doi.org\/10.5306\/wjco.v5.i5.990.","journal-title":"World J Clin Oncol"},{"issue":"3","key":"1232_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153\u201366. https:\/\/doi.org\/10.1038\/nrc2602.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1232_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez M, Malumbres M. Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell. 2020;37(4):514\u201329. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.010.","journal-title":"Cancer Cell"},{"issue":"11","key":"1232_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;28(11):911\u201325. https:\/\/doi.org\/10.1016\/j.tcb.2018.07.002.","journal-title":"Trends Cell Biol"},{"key":"1232_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","volume":"45","author":"E Hamilton","year":"2016","unstructured":"Hamilton E, Infante JR. Targeting CDK4\/6 in patients with cancer. Cancer Treat Rev. 2016;45:129\u201338. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.002.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1232_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","volume":"34","author":"ME Klein","year":"2018","unstructured":"Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4\/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell. 2018;34(1):9\u201320. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.023.","journal-title":"Cancer Cell"},{"issue":"4","key":"1232_CR10","doi-asserted-by":"publisher","first-page":"C19","DOI":"10.1530\/ERC-11-0097","volume":"18","author":"CA Lange","year":"2011","unstructured":"Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer. 2011;18(4):C19\u201324. https:\/\/doi.org\/10.1530\/ERC-11-0097.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"1232_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O'Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417\u201330. https:\/\/doi.org\/10.1038\/nrclinonc.2016.26.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1232_CR12","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djs002","volume":"104","author":"PJ Roberts","year":"2012","unstructured":"Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, et al. Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy. JNCI J Natl Cancer Inst. 2012;104(6):476\u201387. https:\/\/doi.org\/10.1093\/jnci\/djs002.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"10226","key":"1232_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Zangardi M, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(20)30165-3.","journal-title":"Lancet"},{"key":"1232_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918786451","volume":"10","author":"S Pernas","year":"2018","unstructured":"Pernas S, Tolaney SM, Winer EP, Goel S. CDK4\/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018;10:1758835918786451. https:\/\/doi.org\/10.1177\/1758835918786451.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"1232_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1053\/j.seminoncol.2018.01.002","volume":"44","author":"SC Scott","year":"2017","unstructured":"Scott SC, Lee SS, Abraham J. Mechanisms of therapeutic CDK4\/6 inhibition in breast cancer. Semin Oncol. 2017;44(6):385\u201394. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.01.002.","journal-title":"Semin Oncol"},{"issue":"20","key":"1232_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"issue":"32","key":"1232_CR17","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1232_CR18","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"issue":"4","key":"1232_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1903765.","journal-title":"N Engl J Med"},{"issue":"24","key":"1232_CR20","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465\u201372. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1232_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1911149.","journal-title":"N Engl J Med"},{"issue":"25","key":"1232_CR22","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1232_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2. JAMA Oncol. 2020;6(1):116\u201324. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1232_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1232_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor\u2013positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1505270.","journal-title":"N Engl J Med"},{"issue":"20","key":"1232_CR26","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1810527.","journal-title":"N Engl J Med"},{"issue":"1","key":"1232_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)71159-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1232_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-020-05708-5","volume":"183","author":"RS Finn","year":"2020","unstructured":"Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2\u2212 advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020;183(2):419\u201328. https:\/\/doi.org\/10.1007\/s10549-020-05708-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1232_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.01286","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Fasching PA, Patel R, Verma S, Chia S, Hu C, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42(9):994\u20131000. https:\/\/doi.org\/10.1200\/JCO.23.01286.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1232_CR30","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdy155.","journal-title":"Ann Oncol"},{"issue":"10","key":"1232_CR31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2114663.","journal-title":"N Engl J Med"},{"issue":"5","key":"1232_CR32","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-2993","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2\u2212 advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2993.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1232_CR33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35(8):718\u201327. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005.","journal-title":"Ann Oncol"},{"issue":"9","key":"1232_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105570","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Cristofanilli M, Martin M, Loi S, Im SA, Harbeck N, et al. Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR-positive\/HER2-negative metastatic breast cancer in United States routine clinical practice. ESMO Open. 2025;10(9):105570. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105570.","journal-title":"ESMO Open."},{"issue":"3","key":"1232_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-021-01470-3","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317\u201331. https:\/\/doi.org\/10.1007\/s40265-021-01470-3.","journal-title":"Drugs"},{"issue":"5","key":"1232_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825\u201337. https:\/\/doi.org\/10.1007\/s10637-014-0120-7.","journal-title":"Invest New Drugs"},{"key":"1232_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102086","volume":"90","author":"A Desnoyers","year":"2020","unstructured":"Desnoyers A, Nadler MB, Kumar V, Saleh RR, Amir E. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: a network meta-analysis. Cancer Treat Rev. 2020;90:102086. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102086.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1232_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","volume":"18","author":"S Thibault","year":"2019","unstructured":"Thibault S, Porter LA, Whittaker S, Crawford L, Rameh L, Barrett JC, et al. Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary pharmacology. Mol Cancer Ther. 2019;18(2):257\u201366. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0734","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1232_CR39","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","volume":"59","author":"SL Groenland","year":"2020","unstructured":"Groenland SL, Martinez-Chavez A, van Dongen MGJ, Beijnen JH, Schinkel AH, Huitema ADR. Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib. Clin Pharmacokinet. 2020;59(12):1501\u201320. https:\/\/doi.org\/10.1007\/s40262-020-00930-x.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1232_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncology. 2023;24(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5.","journal-title":"Lancet Oncology"},{"issue":"9","key":"1232_CR41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01740","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi P, Johnston SRD, Toi M, Martin M, Shao ZM, Zhang Q, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42(9):987\u201393. https:\/\/doi.org\/10.1200\/JCO.23.01740.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1232_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.annonc.2025.11.012","volume":"37","author":"S Johnston","year":"2026","unstructured":"Johnston S, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37(2):155\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2025.11.012.","journal-title":"Ann Oncol"},{"issue":"12","key":"1232_CR43","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2400670","volume":"390","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Fasching PA, Hurvitz SA, Neven P, Stroyakovskiy D, Im SA, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2400670.","journal-title":"N Engl J Med"},{"issue":"11","key":"1232_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105858","volume":"10","author":"J Crown","year":"2025","unstructured":"Crown J, Slamon D, Im SA, Fasching PA, Neven P, Stroyakovskiy D, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10(11):105858. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105858.","journal-title":"ESMO Open."},{"issue":"2","key":"1232_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","volume":"22","author":"EL Mayer","year":"2021","unstructured":"Mayer EL, Dueck AC, Martin M, Burstein HJ, Goetz MP, Forero-Torres A, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(20)30642-2.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1232_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.annonc.2025.11.018","volume":"37","author":"EL Mayer","year":"2026","unstructured":"Mayer EL, Dueck AC, Martin M, Burstein HJ, Goetz MP, Forero-Torres A, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42\/AFT-05\/PrE0109\/BIG-14-13). Ann Oncol. 2026;37(2):271\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2025.11.018.","journal-title":"Ann Oncol"},{"issue":"14","key":"1232_CR47","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl S, Marm\u00e9 F, Martin M, Untch M, Bonnefoi H, Kim SB, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014the Penelope-B trial. J Clin Oncol. 2021;39(14):1518\u201330. https:\/\/doi.org\/10.1200\/JCO.20.03639.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1232_CR48","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.annonc.2025.03.012","volume":"36","author":"S Loibl","year":"2025","unstructured":"Loibl S, Marm\u00e9 F, Martin M, Untch M, Bonnefoi H, Kim SB, et al. Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+\/HER2\u2212 breast cancer and residual disease after neoadjuvant chemotherapy. Ann Oncol. 2025;36(7):832\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.012.","journal-title":"Ann Oncol"},{"issue":"11","key":"1232_CR49","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34(11):970\u201386. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.009.","journal-title":"Ann Oncol"},{"issue":"11","key":"1232_CR50","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O'Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 Trial. Cancer Discov. 2018;8(11):1390\u2013403. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0264.","journal-title":"Cancer Discov"},{"issue":"1","key":"1232_CR51","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1038\/s41467-022-32910-4","volume":"13","author":"M Palafox","year":"2022","unstructured":"Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, et al. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER-positive breast cancer. Nat Commun. 2022;13(1):5258. https:\/\/doi.org\/10.1038\/s41467-022-32910-4.","journal-title":"Nat Commun"},{"issue":"8","key":"1232_CR52","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1390.","journal-title":"Cancer Discov"},{"issue":"3","key":"1232_CR53","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/annonc\/mdx784","volume":"29","author":"R Condorelli","year":"2018","unstructured":"Condorelli R, Spring L, O\u2019Shaughnessy J, Lacroix L, Bailleux C, Scott V, et al. Polyclonal RB1 mutations and acquired resistance to CDK4\/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018;29(3):640\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdx784.","journal-title":"Ann Oncol"},{"issue":"16","key":"1232_CR54","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","volume":"36","author":"C Yang","year":"2017","unstructured":"Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017;36(16):2255\u201364. https:\/\/doi.org\/10.1038\/onc.2016.379.","journal-title":"Oncogene"},{"issue":"6","key":"1232_CR55","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway. Cancer Cell. 2018;34(6):893-905.e8. https:\/\/doi.org\/10.1016\/j.ccell.2018.11.006.","journal-title":"Cancer Cell"},{"issue":"2","key":"1232_CR56","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2159-8290.CD-21-0459","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Jiang Y, Liang Y, Li Z, Chen X, Zhang C, et al. INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors. Cancer Discov. 2022;12(2):356\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0459.","journal-title":"Cancer Discov"},{"issue":"8","key":"1232_CR57","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Can Res. 2016;76(8):2301\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0728.","journal-title":"Can Res"},{"issue":"14","key":"1232_CR58","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2019;37(14):1169\u201378. https:\/\/doi.org\/10.1200\/JCO.18.00925.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1232_CR59","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaoncol.2023.0683","volume":"9","author":"TC Haddad","year":"2023","unstructured":"Haddad TC, Tehfe M, Kamel-Reid S, Rimawi MF, Hamilton EP, Neven P, et al. Evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial. JAMA Oncol. 2023;9(6):815\u201324. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0683.","journal-title":"JAMA Oncol"},{"issue":"suppl","key":"1232_CR60","doi-asserted-by":"publisher","first-page":"TPS1125","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS1125","volume":"43","author":"PPB Advani","year":"2025","unstructured":"Advani PPB, Braga SADS, Brufsky AM, Giridhar K, Mayer EL, McCann KE, et al. Alisertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2\u2212) recurrent or metastatic breast cancer: the phase 2 ALISCA-Breast1 study. J Clin Oncol. 2025;43(suppl):TPS1125. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS1125.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1232_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119346","volume":"1869","author":"MC Papadimitriou","year":"2022","unstructured":"Papadimitriou MC, Vassilakopoulou M, Papadimitriou CA. Resistance to CDK4\/6 inhibition: mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer. Biochim Biophys Acta (Molecular Cell Research). 2022;1869(12):119346. https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119346.","journal-title":"Biochim Biophys Acta (Molecular Cell Research)."},{"issue":"20","key":"1232_CR62","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1158\/1078-0432.CCR-17-0427","volume":"23","author":"L Formisano","year":"2017","unstructured":"Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, et al. Association of FGFR1 with ER\u03b1 maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer. Clin Cancer Res. 2017;23(20):6138\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0427.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1232_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373. https:\/\/doi.org\/10.1038\/s41467-019-09068-2.","journal-title":"Nat Commun"},{"issue":"1","key":"1232_CR64","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41698-025-00433-2","volume":"9","author":"N Martinez-Ja\u00f1ez","year":"2025","unstructured":"Martinez-Ja\u00f1ez N, De Angelis C, Formisano L, Hanker AB, Sudhan DR, Guerriero JL, et al. Co-clinical trial targeting ER, FGFR and CDK4\/6 in resistant hormone-positive breast cancer with FGFR alterations. NPJ Precis Oncol. 2025;9(1):343. https:\/\/doi.org\/10.1038\/s41698-025-00433-2.","journal-title":"NPJ Precis Oncol"},{"key":"1232_CR65","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-RF01-04","author":"S Damodaran","year":"2023","unstructured":"Damodaran S, Juric D, Rugo HS, Jhaveri KL, Park YH, Sohn J, et al. Abstract RF01-04: Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced\/metastatic HR+\/HER2\u2212 breast cancer harboring high-level FGFR1 gene amplification. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-RF01-04.","journal-title":"Cancer Res"},{"issue":"4","key":"1232_CR66","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37(4):496\u2013513. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.009.","journal-title":"Cancer Cell"},{"issue":"10","key":"1232_CR67","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.annonc.2023.07.008","volume":"34","author":"K Jhaveri","year":"2023","unstructured":"Jhaveri K, Jhaveri KL, Turner NC, Hamilton EP, Loi S, Saji S, et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023;34(10):885\u201398. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.008.","journal-title":"Ann Oncol"},{"issue":"2","key":"1232_CR68","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208\u201317. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.011.","journal-title":"Ann Oncol"},{"issue":"813","key":"1232_CR69","doi-asserted-by":"publisher","first-page":"eadq5492","DOI":"10.1126\/scitranslmed.adq5492","volume":"17","author":"ZY Zheng","year":"2025","unstructured":"Zheng ZY, Wang Y, Chen Y, Liu Y, Li J, Zhang X, et al. NF1-depleted ER+ breast cancer promotes endocrine resistance. Science Translational Medicine. 2025;17(813):eadq5492. https:\/\/doi.org\/10.1126\/scitranslmed.adq5492.","journal-title":"Science Translational Medicine."},{"key":"1232_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105828","volume":"118","author":"MR Lloyd","year":"2025","unstructured":"Lloyd MR, Wander SA, Gong X, Wang Y, Teo ZL, Buendia-Buendia JE, et al. A bedside-to-bench translational analysis of NF1 alterations and CDK4\/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer. EBioMedicine. 2025;118:105828. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105828.","journal-title":"EBioMedicine"},{"issue":"19","key":"1232_CR71","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-23-0465","volume":"83","author":"J Navarro-Yepes","year":"2023","unstructured":"Navarro-Yepes J, Llop-Guevara A, L\u00f3pez-Casas PP, Villacampa G, Scaltriti M, Palafox M, et al. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Can Res. 2023;83(19):3264\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0465.","journal-title":"Can Res"},{"issue":"9","key":"1232_CR72","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.6004\/jnccn.2021.7024","volume":"19","author":"SA Wander","year":"2021","unstructured":"Wander SA, Zangardi M, Niemierko A, Wilson TR, Cohen O, Freedman RA, et al. Clinical outcomes with abemaciclib after prior CDK4\/6 inhibitor progression in breast cancer: a multicenter experience. J Natl Compr Canc Netw. 2021;19(9):1040\u20137. https:\/\/doi.org\/10.6004\/jnccn.2021.7024.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1232_CR73","doi-asserted-by":"publisher","first-page":"28579","DOI":"10.1038\/s41598-025-28579-2","volume":"15","author":"M Algethami","year":"2025","unstructured":"Algethami M, Alotaibi H, Alharbi K, Alghamdi A, Alshammari F, Alenzi FQ, et al. Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities. Sci Rep. 2025;15(1):28579. https:\/\/doi.org\/10.1038\/s41598-025-28579-2.","journal-title":"Sci Rep"},{"issue":"1","key":"1232_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324. https:\/\/doi.org\/10.1038\/s41467-017-00965-y.","journal-title":"Nat Commun"},{"issue":"1","key":"1232_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03215-x","volume":"9","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018;9(1):896. https:\/\/doi.org\/10.1038\/s41467-018-03215-x.","journal-title":"Nat Commun"},{"key":"1232_CR76","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00002","volume":"6","author":"US Asghar","year":"2022","unstructured":"Asghar US, Kanani R, Roylance R, Mittal K, Eaglestone S, Baird R, et al. Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast cancer. JCO Precis Oncol. 2022;6:e2100002. https:\/\/doi.org\/10.1200\/PO.21.00002.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1232_CR77","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13058-017-0913-7","volume":"19","author":"NA Bagegni","year":"2017","unstructured":"Bagegni NA, Tao Y, Ademuyiwa FO, Wang Z, Young GS, McKenzie AJ, et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4\/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res. 2017;19(1):123. https:\/\/doi.org\/10.1186\/s13058-017-0913-7.","journal-title":"Breast Cancer Res"},{"key":"1232_CR78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2019.04.011","volume":"114","author":"A McCartney","year":"2019","unstructured":"McCartney A, Bonechi M, De Luca F, Biagioni C, Curigliano G, Moretti E, et al. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). Eur J Cancer. 2019;114:55\u201366. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.011.","journal-title":"Eur J Cancer"},{"issue":"25","key":"1232_CR79","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","volume":"34","author":"C Fribbens","year":"2016","unstructured":"Fribbens C, O\u2019Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.67.3061.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1232_CR80","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1038\/s41467-025-60133-5","volume":"16","author":"V Roulstone","year":"2025","unstructured":"Roulstone V, Pedersen M, Kyula JN, Mansfield D, Khan AA, McEntee G, et al. Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion. Nat Commun. 2025;16(1):4855. https:\/\/doi.org\/10.1038\/s41467-025-60133-5","journal-title":"Nat Commun"},{"issue":"6","key":"1232_CR81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143762","volume":"132","author":"IS Chan","year":"2022","unstructured":"Chan IS, Ewald AJ. The changing role of natural killer cells in cancer metastasis. J Clin Invest. 2022;132(6):e143762. https:\/\/doi.org\/10.1172\/JCI143762.","journal-title":"J Clin Invest"},{"issue":"9","key":"1232_CR82","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202002077","volume":"219","author":"IS Chan","year":"2020","unstructured":"Chan IS, Kn\u00fatsd\u00f3ttir H, Ramakrishnan G, Padmanaban V, Warrier M, Ramirez JC, et al. Cancer cells educate natural killer cells to a metastasis-promoting cell state. J Cell Biol. 2020;219(9):e202001134. https:\/\/doi.org\/10.1083\/jcb.202002077.","journal-title":"J Cell Biol"},{"issue":"6421","key":"1232_CR83","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1126\/science.aas9090","volume":"362","author":"M Ruscetti","year":"2018","unstructured":"Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362(6421):1416\u201322. https:\/\/doi.org\/10.1126\/science.aas9090.","journal-title":"Science"},{"issue":"7668","key":"1232_CR84","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135. https:\/\/doi.org\/10.1038\/nature23465.","journal-title":"Nature"},{"key":"1232_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104010","volume":"79","author":"F Scirocchi","year":"2022","unstructured":"Scirocchi F, et al. Immune effects of CDK4\/6 inhibitors in patients with HR+\/HER2\u2212 metastatic breast cancer: relief from immunosuppression is associated with clinical response. EBioMedicine. 2022;79:104010. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104010.","journal-title":"EBioMedicine"},{"issue":"11","key":"1232_CR86","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","volume":"20","author":"G Petroni","year":"2020","unstructured":"Petroni G, Sibilio L, Castoldi F, Sold\u00e0 G, Fitting S, Dislich B, et al. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol. 2020;20(11):669\u201379. https:\/\/doi.org\/10.1038\/s41577-020-0300-y","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1232_CR87","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.082","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amalfitano A, et al. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2978\u201394. https:\/\/doi.org\/10.1016\/j.celrep.2018.02.082.","journal-title":"Cell Rep"},{"issue":"1","key":"1232_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108944","volume":"35","author":"RV Uzhachenko","year":"2021","unstructured":"Uzhachenko RV, Shanker A, Thirunavukkarasu N, Da Silva DM, McGaha TL, Sharrow SO, et al. Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 2021;35(1):108944. https:\/\/doi.org\/10.1016\/j.celrep.2021.108944.","journal-title":"Cell Rep"},{"issue":"10","key":"1232_CR89","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1158\/2159-8290.CD-20-1429","volume":"11","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott EJ, Pham TQ, McMahon KM, Valigo V, Ott PA, Dang Y, et al. CDK4\/6 inhibition promotes antitumor immunity through the induction of T-cell memory. Cancer Discov. 2021;11(10):2582\u2013601. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1429.","journal-title":"Cancer Discov"},{"issue":"10","key":"1232_CR90","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1453","volume":"11","author":"M Heckler","year":"2021","unstructured":"Heckler M, Yeh JE, Edelman H, Ngo B, Cortez MA, Winkler JD, et al. Inhibition of CDK4\/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021;11(10):2564\u201381. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1453.","journal-title":"Cancer Discov"},{"issue":"3","key":"1232_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002084","volume":"9","author":"C Egelston","year":"2021","unstructured":"Egelston C, Guo W, Yost S, Lee JS, Rose D, Avalos C, et al. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4\/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. J Immunother Cancer. 2021;9(3):e002084. https:\/\/doi.org\/10.1136\/jitc-2020-002084.","journal-title":"J Immunother Cancer"},{"issue":"7686","key":"1232_CR92","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91\u20135. https:\/\/doi.org\/10.1038\/nature25015.","journal-title":"Nature"},{"key":"1232_CR93","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2021.08.003","volume":"154","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Im SA, Chia S, et al. Phase I\/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur J Cancer. 2021;154:11\u201320. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.003.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1232_CR94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41523-022-00436-9","volume":"8","author":"SH Rugo","year":"2022","unstructured":"Rugo SH, Beck JT, Liu MC, et al. Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: phase 1b study. NPJ Breast Cancer. 2022;8(1):35. https:\/\/doi.org\/10.1038\/s41523-022-00436-9.","journal-title":"NPJ Breast Cancer."},{"issue":"1","key":"1232_CR95","doi-asserted-by":"publisher","first-page":"11659","DOI":"10.1038\/s41467-025-66590-2","volume":"16","author":"A Papagiannis","year":"2025","unstructured":"Papagiannis A, Majjaj S, Duhoux FP, Agostinetto E, Stanciu AM, Vanhulst T, et al. Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: the NeoRHEA phase 2 study. Nat Commun. 2025;16(1):11659. https:\/\/doi.org\/10.1038\/s41467-025-66590-2.","journal-title":"Nat Commun"},{"issue":"1","key":"1232_CR96","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41523-024-00625-7","volume":"10","author":"T Pascual","year":"2024","unstructured":"Pascual T, Fernandez-Martinez A, Agrawal Y, Pfefferle AD, Chic N, Bras\u00f3-Maristany F, et al. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ Breast Cancer. 2024;10(1):20. https:\/\/doi.org\/10.1038\/s41523-024-00625-7.","journal-title":"NPJ Breast Cancer."},{"issue":"24","key":"1232_CR97","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41(24):4004\u201313. https:\/\/doi.org\/10.1200\/JCO.22.02392.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1232_CR98","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH Trial. J Clin Oncol. 2025;43(9):1101\u201312. https:\/\/doi.org\/10.1200\/JCO-24-02086.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1232_CR99","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et al. PACE: a randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer. J Clin Oncol. 2024;42(17):2050\u201360. https:\/\/doi.org\/10.1200\/JCO.23.01940.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1232_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105506","volume":"10","author":"R Jeselsohn","year":"2025","unstructured":"Jeselsohn R, Fu J, Ren Y, Mahtani R, Ma C, DeMichele A, et al. Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4\/6 inhibitor in the PACE phase II trial for metastatic HR-positive\/HER2-negative breast cancer. ESMO Open. 2025;10(8):105506. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105506.","journal-title":"ESMO Open"},{"issue":"20","key":"1232_CR101","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1813904.","journal-title":"N Engl J Med"},{"issue":"12","key":"1232_CR102","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25(12):e629\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(24)00673-9.","journal-title":"Lancet Oncol"},{"issue":"28","key":"1232_CR103","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1200\/JCO.25.00840","volume":"43","author":"S Wedam","year":"2025","unstructured":"Wedam S, Narayan P, Gittleman H, Cheng J, Bhatnagar V, Sabit H, et al. US Food and Drug Administration approval summary: inavolisib with palbociclib and fulvestrant for endocrine-resistant advanced breast cancer. J Clin Oncol. 2025;43(28):3123\u201331. https:\/\/doi.org\/10.1200\/JCO.25.00840.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1232_CR104","doi-asserted-by":"publisher","first-page":"TPS1136","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1136","volume":"42","author":"D Juric","year":"2024","unstructured":"Juric D, Kalinsky K, Im SA, Ciruelos E, Bianchini G, Barrios CH Sr, et al. INAVO121: phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with HR+, HER2\u2013, PIK3CA-mutated locally advanced or metastatic breast cancer. J Clin Oncol. 2024;42(16_suppl):TPS1136. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS1136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1232_CR105","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-23-0926","volume":"14","author":"A Varkaris","year":"2024","unstructured":"Varkaris A, Fece de la Cruz F, Martin EE, Norden BL, Chevalier N, Kehlmann AM, et al. Allosteric PI3K\u03b1 inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discov. 2024;14(2):227\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0926.","journal-title":"Cancer Discov"},{"issue":"11","key":"1232_CR106","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/2159-8290.CD-23-0598","volume":"13","author":"AL Kearney","year":"2023","unstructured":"Kearney AL, Vasan N. A new wave of PI3K\u03b1 inhibitors. Cancer Discov. 2023;13(11):2313\u20135. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0598.","journal-title":"Cancer Discov"},{"issue":"22","key":"1232_CR107","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2304579","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2304579.","journal-title":"N Engl J Med"},{"issue":"1","key":"1232_CR108","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13058-021-01474-0","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, Spring LM, Bardia A, Wander SA.\u00a0ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23(1):85. https:\/\/doi.org\/10.1186\/s13058-021-01474-0.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1232_CR109","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ccell.2017.12.004","volume":"33","author":"R Jeselsohn","year":"2018","unstructured":"Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell. 2018;33(2):173-186.e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.12.004.","journal-title":"Cancer Cell"},{"issue":"10063","key":"1232_CR110","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32505-6","volume":"388","author":"JFR Robertson","year":"2016","unstructured":"Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997\u20133005. https:\/\/doi.org\/10.1016\/S0140-6736(16)32505-6.","journal-title":"Lancet"},{"issue":"10","key":"1232_CR111","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar WJ, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664\u201370. https:\/\/doi.org\/10.1200\/JCO.2007.13.5822.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1232_CR112","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/cancers16030619","volume":"16","author":"N Neupane","year":"2024","unstructured":"Neupane N, Boyer M, Manikhas GM, Kalinsky K, Zuo C, Biganzoli L, et al. Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer. Cancers (Basel). 2024;16(3):619. https:\/\/doi.org\/10.3390\/cancers16030619.","journal-title":"Cancers (Basel)."},{"issue":"28","key":"1232_CR113","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani V, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246\u201356. https:\/\/doi.org\/10.1200\/JCO.22.00338.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1232_CR114","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-0552","volume":"30","author":"A Bardia","year":"2024","unstructured":"Bardia A, Cort\u00e9s J, Bidard FC, Neven P, Garcia-S\u00e1enz J, Aftimos P, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and clinical subgroups. Clin Cancer Res. 2024;30(19):4299\u2013309. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0552.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1232_CR115","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1200\/JCO.23.02112","volume":"42","author":"M Shah","year":"2024","unstructured":"Shah M, Lingam H, Gao X, Gittleman H, Fiero MH, Krol D, et al. US Food and Drug Administration approval summary: elacestrant for estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. J Clin Oncol. 2024;42(10):1193\u2013201. https:\/\/doi.org\/10.1200\/JCO.23.02112.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1232_CR116","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11523-025-00915-z","volume":"20","author":"EP Hamilton","year":"2025","unstructured":"Hamilton EP, Jeselsohn RM, Vahdat LT, Hurvitz SA. Proteolysis targeting chimera (PROTAC) estrogen receptor degraders for treatment of estrogen receptor-positive advanced breast cancer. Target Oncol. 2025;20(3):431\u201344. https:\/\/doi.org\/10.1007\/s11523-025-00915-z.","journal-title":"Target Oncol"},{"issue":"32","key":"1232_CR117","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.2217\/fon-2024-0341","volume":"20","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, et al. VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer. Future Oncol. 2024;20(32):2447\u201355. https:\/\/doi.org\/10.2217\/fon-2024-0341.","journal-title":"Future Oncol"},{"issue":"7_Supplement","key":"1232_CR118","doi-asserted-by":"publisher","first-page":"LB179","DOI":"10.1158\/1538-7445.AM2024-LB179","volume":"84","author":"W Du","year":"2024","unstructured":"Du W, Tu Z, Qin D, Li H, Duan J, Liu S, et al. Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer. Cancer Res. 2024;84(7_Supplement):LB179. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-LB179.","journal-title":"Can Res"},{"issue":"S4_Suppl","key":"1232_CR119","doi-asserted-by":"publisher","first-page":"PS12","DOI":"10.1158\/1538-7445.AM2021-PS12-23","volume":"81","author":"M Korpal","year":"2021","unstructured":"Korpal M, Craig F, Puyang X, Zhang Z, Wu Z, Bankaet D, et al. Development of H3B\u20136545, a first-in-class oral selective ER covalent antagonist (SERCA), for treatment of ER\u03b1WT and ER\u03b1MUT breast cancer. Cancer Res. 2021;81(S4_Suppl):PS12-23. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-PS12-23.","journal-title":"Cancer Res"},{"issue":"15_suppl","key":"1232_CR120","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1200\/JCO.2021.39.15_suppl.1018","volume":"39","author":"EP Hamilton","year":"2021","unstructured":"Hamilton EP, Wang JS, Pluard TJ, Johnston SRD, Morikawa A, Dees EC, et al. Phase I\/II study of H3B\u20136545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer [abstract]. J Clin Oncol. 2021;39(15_suppl):1018. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.1018.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1232_CR121","doi-asserted-by":"publisher","first-page":"TPS1100","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1100","volume":"39","author":"S Johnston","year":"2021","unstructured":"Johnston S, Pluard T, Hamilton E, Morikawa A, Dees EC, Wang J, et al. Phase 1b study of H3B\u20136545 in combination with palbociclib in women with metastatic estrogen receptor\u2013positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer [abstract]. J Clin Oncol. 2021;39(15_suppl):TPS1100. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS1100.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1232_CR122","doi-asserted-by":"publisher","first-page":"TPS1131","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS1131","volume":"43","author":"B Pistilli","year":"2025","unstructured":"Pistilli B, Sohn J, Schmid P, Bellet M, Del Mastro L, Meisel JL, et al. OPERA-01: a randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4\/6 inhibitors. J Clin Oncol. 2025;43(16_suppl):TPS1131.ClinicalTrials.gov ID NCT06016738 https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS1131.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1232_CR123","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172091","volume":"133","author":"HL Chang","year":"2023","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest. 2023;133(18):e172091. https:\/\/doi.org\/10.1172\/JCI172091.","journal-title":"J Clin Investig"},{"issue":"1","key":"1232_CR124","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"issue":"8","key":"1232_CR125","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29(8):2110\u201320. https:\/\/doi.org\/10.1038\/s41591-023-02478-2.","journal-title":"Nat Med"},{"issue":"22","key":"1232_CR126","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2403855","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2403855.","journal-title":"N Engl J Med"},{"issue":"48","key":"1232_CR127","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48):28989\u20139006. https:\/\/doi.org\/10.18632\/oncotarget.25615.","journal-title":"Oncotarget"},{"issue":"8","key":"1232_CR128","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1814213.","journal-title":"N Engl J Med"},{"issue":"10411","key":"1232_CR129","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-2","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D,\u00a0et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(23)01245-2.","journal-title":"Lancet"},{"issue":"16_suppl","key":"1232_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1557-3265.SABCS25-GS1-09.GS1-09","volume":"42","author":"K Jhaveri","year":"2024","unstructured":"Jhaveri K, Park Y, Barrios C, Curigliano G, Iwata H, Cort\u00e9s J, et al. Sacituzumab govitecan vs chemotherapy as first therapy for hormone receptor-positive\/HER2-negative metastatic breast cancer.\u00a0Clin Cancer Res. 2026;32(4_Suppl):GS1-09.\u00a0https:\/\/doi.org\/10.1158\/1557-3265.SABCS25-GS1-9.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1232_CR131","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.24.00920","volume":"20","author":"A Bardia","year":"2024","unstructured":"Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol. 2025;43(3):285-296. https:\/\/doi.org\/10.1200\/JCO.24.00920.","journal-title":"Future Oncol"},{"issue":"6","key":"1232_CR132","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2412345","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard FC, Kaklamani V, Neven P, Streich G, Montero AJ, Forget F, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025;393(6):569\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2412345.","journal-title":"N Engl J Med"},{"issue":"12","key":"1232_CR133","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2415678","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Turner NC, Bardia A, Niikura N, Bellet M, Barrios CH, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392(12):1189\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2415678.","journal-title":"N Engl J Med"},{"issue":"4","key":"1232_CR134","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.annonc.2025.11.018","volume":"37","author":"KL Jhaveri","year":"2026","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim S-B, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial. Ann Oncol. 2026;37(4):532\u201343. https:\/\/doi.org\/10.1016\/j.annonc.2025.11.018.","journal-title":"Ann Oncol"},{"issue":"17_suppl","key":"1232_CR135","doi-asserted-by":"publisher","first-page":"LBA1006","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA1006","volume":"44","author":"NC Turner","year":"2026","unstructured":"Turner NC, Jhaveri KL, Bardia A, Niikura N, Bellet M, Barrios CH, et al. Giredestrant plus palbociclib versus letrozole plus palbociclib as first-line therapy in ER-positive, HER2-negative advanced breast cancer (persevERA BC). J Clin Oncol. 2026;44(17_suppl):LBA1006. https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA1006.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1232_CR136","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa2511218","volume":"394","author":"O Metzger","year":"2026","unstructured":"Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, et al. Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med. 2026;394(5):451\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2501123.","journal-title":"N Engl J Med"},{"issue":"8","key":"1232_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116140","volume":"44","author":"ES Knudsen","year":"2025","unstructured":"Knudsen ES, Witkiewicz AK, Sanidas I, Rubin SM. Targeting CDK2 for cancer therapy. Cell Rep. 2025;44(8):116140. https:\/\/doi.org\/10.1016\/j.celrep.2025.116140.","journal-title":"Cell Rep"},{"issue":"1","key":"1232_CR138","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41523-025-00921-1","volume":"11","author":"NC House","year":"2025","unstructured":"House NC, Chen MM, Khazaei S, Brown V, Ramsden P, Peng DH, et al. CDK2 inhibition enhances CDK4\/6 inhibitor antitumor activity in breast cancer PDX models. NPJ Breast Cancer. 2025;11(1):135. https:\/\/doi.org\/10.1038\/s41523-025-00921-1.","journal-title":"NPJ Breast Cancer."},{"issue":"2_Suppl","key":"1232_CR139","doi-asserted-by":"publisher","first-page":"S495","DOI":"10.1016\/j.annonc.2024.08.685","volume":"35","author":"TA Yap","year":"2024","unstructured":"Yap TA, Yan F, Sadeghi S, Lin TT, Liu F, Malky L, et al. Phase Ib\/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors. Ann Oncol. 2024;35(2_Suppl):S495\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.685.","journal-title":"Ann Oncol"},{"issue":"3","key":"1232_CR140","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2025.02.006","volume":"43","author":"CL Palmer","year":"2025","unstructured":"Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, et al. CDK4-selective inhibition improves antitumor efficacy and safety. Cancer Cell. 2025;43(3):464-481.e14. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.006.","journal-title":"Cancer Cell"},{"issue":"6","key":"1232_CR141","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"P Zhang","year":"2023","unstructured":"Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z,\u00a0et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021;27(11):1904-9. https:\/\/doi.org\/10.1038\/s41591-021-01562-9.","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"1232_CR142","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1200\/JCO.2024.42.16_suppl.3111","volume":"42","author":"H Majeski","year":"2024","unstructured":"Majeski H, Chahal K, Pasis A, Carlson C, Liu Q, Shakya A, et al. Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+\/HER2- breast cancer and glioblastoma multiforme. J Clin Oncol. 2024;42(16_suppl):3111. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3111.","journal-title":"J Clin Oncol"},{"key":"1232_CR143","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00031","volume":"2","author":"S David","year":"2025","unstructured":"David S, Connolly E, Bressel M, Tan J, Hanna GG, Alomran R, et al. Stereotactic ablative body radiotherapy for oligoprogressive estrogen receptor\u2013positive breast cancer (TROG 20.03 AVATAR): a phase II prospective multicenter trial. JCO Oncol Adv 2, e2500031(2025). https:\/\/doi.org\/10.1200\/OA-25-00031.","journal-title":"JCO Oncol Adv"},{"issue":"2","key":"1232_CR144","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8(2):216\u201333. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0915.","journal-title":"Cancer Discov"},{"key":"1232_CR145","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-0716-2160-8_14","volume":"2463","author":"IS Chan","year":"2022","unstructured":"Chan IS, Ewald AJ. Organoid co-culture NK cell methods. Methods Mol Biol. 2022;2463:235\u201350. https:\/\/doi.org\/10.1007\/978-1-0716-2160-8_14.","journal-title":"Methods Mol Biol"},{"key":"1232_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1358583","volume":"12","author":"KE Lake","year":"2024","unstructured":"Lake KE, Colonnetta MM, Smith CA, Saunders K, Martinez-Algarin K, Mohta S, et al. Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneity. Front Cell Dev Biol. 2024;12:1358583. https:\/\/doi.org\/10.3389\/fcell.2024.1358583.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"1232_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101511","volume":"5","author":"L Xu","year":"2024","unstructured":"Xu L, Saunders K, Huang SP, Knutsdottir H, Martinez-Algarin K, Terrazas I, et al. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Rep Med. 2024;5(5):101511. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101511.","journal-title":"Cell Rep Med"},{"issue":"17_suppl","key":"1232_CR148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4","volume":"43","author":"CN Turner","year":"2025","unstructured":"Turner CN, Mayer EL, Park YH, Janni W, Ma CX, Cristofanilli M, et al. Camizestrant + CDK4\/6 inhibitor (CDK4\/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+\/HER2\u2013 advanced breast cancer (ABC): phase 3, double-blind ctDNA-guided SERENA-6 trial. J Clin Oncol. 2025;43)(17_Suppl):LBA4. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA4.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01232-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01232-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01232-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:44Z","timestamp":1790916704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01232-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":148,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01232-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luis Chinea, Caroline Hauer, Khushboo Pal, Hannah L. Chang, and Isaac S. Chan declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflicts of interest\/Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}